BMY - Bristol-Myers Squibb Company
52.59 0.00 (0.00%)
After hours: 5:57PM EST
| Previous Close | 52.85 |
| Open | 53.02 |
| Bid | 0.00 x 1000 |
| Ask | 54.00 x 2200 |
| Day's Range | 52.30 - 53.32 |
| 52 Week Range | 46.94 - 70.05 |
| Volume | 4,586,636 |
| Avg. Volume | 7,192,918 |
| Market Cap | 85.837B |
| Beta (3Y Monthly) | 1.37 |
| PE Ratio (TTM) | 233.73 |
| EPS (TTM) | 0.22 |
| Earnings Date | Feb 4, 2019 - Feb 8, 2019 |
| Forward Dividend & Yield | 1.60 (3.03%) |
| Ex-Dividend Date | 2018-10-04 |
| 1y Target Est | 59.47 |
- Zacks•11 hours ago
Bayer (BAYRY) Beats on Q3 Earnings, Revenue Estimates
Bayer (BAYRY) surpasses earnings and sales estimates in the third quarter of 2018 and reiterates outlook for 2018.
- ACCESSWIRE•17 hours ago
Today's Research Reports on Trending Tickers: Nektar Therapeutics and Bristol-Myers Squibb
NEW YORK, NY / ACCESSWIRE / November 13, 2018 / U.S. stocks closed down on Monday as oil prices continued to slide, raising concerns amongst investors. The Dow Jones Industrial Average plunged 2.32 percent ...
- Investor's Business Daily•yesterday
Nektar Bounds Higher On 'Promising Contender' In Cancer Immunotherapy
Nektar Therapeutics bounded higher Monday after its immunotherapy combination with Bristol-Myers Squibb showed promise as a melanoma treatment.
Market Realist•2 days agoAnalyzing Nektar Therapeutics’ Q3 Operational Performance
Nektar Therapeutics (NKTR) incurred general and administrative expenses of $18.72 million in the third quarter of 2018 as compared with $12.06 million in the third quarter of 2017. Nektar Therapeutics expects general and administrative expenses in fiscal 2018 to be higher than they were in fiscal 2017.
Market Realist•2 days agoWhat Nektar Therapeutics’ Bottom-Line Trend Indicates
Nektar Therapeutics’ (NKTR) interest expense decreased marginally to $5.44 million in the third quarter of 2018 as compared with $5.54 million in the year-ago period. Its net interest and other income increased from $1.6 million in the third quarter of 2017 to $11.85 million in the third quarter of 2018 due to higher interest income from investments in debt securities that the company purchased with $1.85 billion it received from collaboration with Bristol-Myers Squibb (BMY) in April 2018. Nektar Therapeutics incurred a net loss of $96.14 million in the third quarter of 2018 as compared with net income of $60.87 million in the year-ago period.
Market Realist•2 days agoHow Nektar Therapeutics’ Gross Margin Trended
Nektar Therapeutics’ (NKTR) non-cash royalty revenue associated with the sale of future royalties increased from $8.07 million in the third quarter of 2017 to $8.37 million in the third quarter of 2018. The significant drop in Nektar’s total revenues was attributable to a decline in license, collaboration, and other revenues, which decreased from $131.11 million in the third quarter of 2017 to $4.87 million in the third quarter of 2018.
- ACCESSWIRE•2 days ago
Today's Research Reports on Trending Tickers: Heron Therapeutics and Bristol-Myers Squibb
According to Willie Delwiche, investment strategist at R.W. Baird, “Oil being down could be a sign that the global economy is in a tough spot.” “The initial reaction to lower oil prices has been that they’ll be a boon for the middle class,” Delwiche said that the view could be inaccurate considering that consumer confidence doesn’t have more chances to grow, and because a smaller part of the American consumer’s budget goes to gasoline than it has in the previous years. The stock recorded a trading volume of 1,456,948 shares, which was above its three months average volume of 998,535 shares. On Friday, shares of Bristol-Myers Squibb recorded a trading volume of 8,107,392 shares, which was above the three months average volume of 7,213,656 shares.
- Motley Fool•2 days ago
How Bristol-Myers Squibb Company Fell $18.8 Billion in October
A failed clinical trial doesn't bode well for the big pharma's lung cancer strategy.
Markit•4 days agoSee what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.
Bristol-Myers Squibb Co NYSE:BMY
- Investor's Business Daily•4 days ago
Highly Rated 'Surgeon' For Biologic-Drug Makers Soars 85% In 2018
Repligen stock is on a rampage this year as it outperforms broad medical-products stocks. The bioprocessing firm has completely transformed, its CEO says.
- Zacks•4 days ago
Catalyst (CPRX) Reports Q3 Loss as Expected & Pipeline Update
Catalyst (CPRX) provides pipeline update and the FDA sets action date of Nov 28, 2018 for its lead pipeline candidate, Firdapse during the third quarter of 2018.
- Zacks•4 days ago
Keryx's (KERX) Loss Narrower Than Expected in Q3, Sales Lag
Keryx's (KERX) sole marketed product generates sales of $26.6 million in the third quarter, up 96% from the year-ago quarter.
- Zacks•5 days ago
The Zacks Analyst Blog Highlights: DXP Enterprises, Bristol-Myers Squibb, EnPro Industries, Illumina and NetApp
The Zacks Analyst Blog Highlights: DXP Enterprises, Bristol-Myers Squibb, EnPro Industries, Illumina and NetApp
- Zacks•5 days ago
Pharma Stock Roundup: LLY, AZN Report Q3 Earnings, PFE Gets FDA Nod for Cancer Drug
Lilly (LLY) and AstraZeneca (AZN) report third-quarter results. Pfizer (PFE) gains FDA approval for a new cancer medicine.
- ACCESSWIRE•5 days ago
Today's Research Reports on Trending Tickers: AstraZeneca and Bristol-Myers Squibb
NEW YORK, NY / ACCESSWIRE / November 9, 2018 / U.S. stocks retreated on Thursday after the Fed left interest rates unchanged and signaled that it would continue to tighten monetary policy at a gradual pace. Charlie Ripley, senior investment strategist at Allianz Investment Management said that, “With no press conference or expectation for policy change, most market participants viewed the November FOMC meeting as more of a non-event. “With only minimal changes to the statement the Fed is remaining vague about policy changes going forward and likely giving the committee more optionality in a changing market environment,” he added.
- Zacks•5 days ago
Bristol-Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know
Bristol-Myers Squibb (BMY) closed the most recent trading day at $52.81, moving -0.34% from the previous trading session.
Reuters•5 days agoStada, Angelini among final bidders for $1 billion Bristol-Myers' UPSA unit - sources
FRANKFURT/LONDON (Reuters) - German drugmaker Stada (STAGn.DE) and Italian healthcare company Angelini are the only industry players to be shortlisted to make final bids for Bristol-Myers Squibb's (BMY.N) French over-the-counter drugs business, four sources close to the deal said. Two private equity firms, CVC Capital Partners and PAI Partners, have also made it through to the final round of the auction for UPSA, the maker of Dafalgan and Efferalgan painkillers, the sources told Reuters.
- Reuters•5 days ago
Stada, Angelini among final bidders for $1 bln Bristol-Myers' UPSA unit - sources
FRANKFURT/LONDON, Nov 8 (Reuters) - German drugmaker Stada and Italian healthcare company Angelini are the only industry players to be shortlisted to make final bids for Bristol-Myers Squibb's French over-the-counter drugs business, four sources close to the deal said. Two private equity firms, CVC Capital Partners and PAI Partners, have also made it through to the final round of the auction for UPSA, the maker of Dafalgan and Efferalgan painkillers, the sources told Reuters.
- Thomson Reuters StreetEvents•5 days ago
Edited Transcript of BMY earnings conference call or presentation 25-Oct-18 2:30pm GMT
Q3 2018 Bristol-Myers Squibb Co Earnings Call
- Zacks•6 days ago
Horizon Pharma (HZNP) Q3 Earnings & Sales Beat, Shares Rise
Shares of Horizon Pharma (HZNP) rise almost 16%, owing to record quarterly sales during the third quarter of 2018.
- Zacks•6 days ago
Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q3
Immune Design (IMDZ) posts narrower-than-expected loss and misses revenue estimates in the third quarter of 2018. It expects to have cash to fund operations in 2021.
- Zacks•6 days ago
Alnylam's (ALNY) Q3 Loss Narrower Than Expected, Sales Miss
Alnylam (ALNY) incurs wider-than-expected loss year over year in the third quarter of 2018 and reiterates guidance for the year.
- Zacks•6 days ago
Democrats Hold Edge in House Battle: 5 Great Picks (Revised)
Drug and defense stocks would hugely benefit from a divided Congress.
- Zacks•6 days ago
Wall Street Likely to Sustain Post-Midterm Rally: 5 Picks
Investors' optimism has been revived on risky assets like equities with a divided U.S. Congress.
Markit•6 days agoSee what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.
Bristol-Myers Squibb Co NYSE:BMY
